In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.

Antimicrobial Agents and Chemotherapy
Jesús GuineaEmilio Bouza

Abstract

Isavuconazole (BAL4815) is a promising novel broad-spectrum triazole in late-stage clinical development that has proven active in vitro against Aspergillus and Candida species. We compared the in vitro activities of this agent with those of voriconazole and fluconazole by the CLSI (formerly NCCLS) M38-A and M27-A2 procedures against a large collection of 1,007 relevant opportunistic fungi collected from 1986 to 2007: Aspergillus spp. (n = 702), Candida spp. (n = 218), Zygomycetes (n = 45), Scedosporium spp. (n = 22), and Fusarium spp. (n = 20). All Candida isolates were from patients with candidemia. For isavuconazole, these techniques were also compared with the Etest. Isavuconazole and voriconazole had MICs at which 50% and 90% of isolates were inhibited (MIC50 and MIC90), respectively, of 1 and 1 microg/ml and 0.5 and 1 microg/ml against Aspergillus spp. and of < or = 0.015 [corrected] and 0.03 microg/ml and 0.25 and 0.125 microg/ml against Candida spp. (including fluconazole-resistant strains). The MIC50 partial and complete inhibition end points of isavuconazole and voriconazole against the non-Aspergillus molds were as follows: 1 and 2 microg/ml and 16 and >16 mug/ml against Zygomycetes; 1 and 4 microg/ml and 0.25 and 0.5...Continue Reading

References

Mar 7, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kieren A MarrLawrence Corey
Sep 25, 2003·Antimicrobial Agents and Chemotherapy·Alicia Gomez-LopezManuel Cuenca-Estrella
Feb 20, 2007·Antimicrobial Agents and Chemotherapy·H SeifertO Cornely

❮ Previous
Next ❯

Citations

Oct 24, 2008·Current Infectious Disease Reports·Patricia MuñozEmilio Bouza
May 2, 2009·The Journal of Antimicrobial Chemotherapy·George R ThompsonThomas F Patterson
Jan 5, 2011·The Journal of Antimicrobial Chemotherapy·Manuel Cuenca-EstrellaThomas R Rogers
Dec 22, 2010·The Journal of Antimicrobial Chemotherapy·Pranatharthi Chandrasekar
Oct 4, 2008·Current Opinion in Hematology·Valerio Del BonoClaudio Viscoli
Jul 9, 2008·Antimicrobial Agents and Chemotherapy·Jesús GuineaEmilio Bouza
Jun 19, 2008·Antimicrobial Agents and Chemotherapy·George R ThompsonThomas F Patterson
Jun 23, 2010·Antimicrobial Agents and Chemotherapy·Jesús GuineaEmilio Bouza
Sep 12, 2012·Antimicrobial Agents and Chemotherapy·Wendy KloezenWendy W J van de Sande
Jan 24, 2009·Antimicrobial Agents and Chemotherapy·Susanne PerkhoferUNKNOWN European Committee on Antimicrobial Susceptibility Testing
Apr 13, 2011·Clinical Microbiology Reviews·Marisa Z R GomesDimitrios P Kontoyiannis
May 6, 2010·Future Microbiology·Cornelia Lass-Flörl
Jul 30, 2014·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Seyedmojtaba SeyedmousaviPaul E Verweij
Aug 12, 2014·International Journal of Antimicrobial Agents·Michael J Dolton, Andrew J McLachlan
Aug 13, 2014·The Journal of Antimicrobial Chemotherapy·Bettina M Knoll
Sep 5, 2013·Antimicrobial Agents and Chemotherapy·Alexander J LepakDavid R Andes
Oct 7, 2011·World Journal of Surgery·Herman Anthony CarneiroEleftherios Mylonakis
Dec 10, 2014·Expert Review of Anti-infective Therapy·Seyedmojtaba SeyedmousaviJohan W Mouton
Oct 7, 2009·Expert Review of Anti-infective Therapy·Maria Teresa FeraAngelina De Sarro
Mar 23, 2011·Expert Review of Anti-infective Therapy·Ozden Türel
Jun 24, 2015·Expert Opinion on Pharmacotherapy·Maria N Chitasombat, Dimitrios P Kontoyiannis
Sep 21, 2013·Expert Opinion on Pharmacotherapy·Richard H DrewJohn R Perfect
Apr 7, 2015·Expert Opinion on Pharmacotherapy·Lorena Botero-CalderonMichael Cohen-Wolkowiez
May 12, 2009·Expert Opinion on Investigational Drugs·Maria J G T RuepingOliver A Cornely
Aug 15, 2009·Expert Opinion on Investigational Drugs·Corrado Girmenia
Feb 22, 2016·Infectious Disease Clinics of North America·Eunice H Wong, Sanjay G Revankar
Jan 23, 2016·IDCases·Matthew B Lockwood, Juan Carlos Rico Crescencio
Feb 7, 2012·Enfermedades infecciosas y microbiología clínica·Jesús Fortún
Dec 7, 2010·International Journal of Antimicrobial Agents·Patricia MuñozEmilio Bouza
Aug 3, 2010·International Journal of Antimicrobial Agents·Toshikazu YamazakiMikio Arisawa
Aug 12, 2009·Infectious Disease Clinics of North America·David J RitchiePatrick M Finnegan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.